Xenetic Biosciences (XBIO) Proxy filing summary

Executive summary

• Proposed all-stock share exchange with Santersus is expected to form a Nasdaq-listed clinical-stage business targeting NETs across multiple therapeutic indications; closing is expected in Q1 2027, subject to conditions.

• The combined pipeline is described as four first-in-class programs, including pivotal-stage sepsis and SLE programs with FDA Breakthrough Device Designations; initial data from a DNase I plus anti-CD19 CAR T study are expected in Q2 2027.

Voting matters and shareholder proposals

• Shareholder approval is required for the proposed transaction; shareholders are urged to review the proxy statement and Form S-1 when filed.

• The board recommends that shareholders vote in favor of the transaction; closing also depends on Nasdaq listing approval for the shares to be issued and other customary conditions.

Board of directors and corporate governance

• The board, acting on the unanimous recommendation of its independent Special Committee, approved the proposed transaction; Santersus’s board also approved it unanimously.